BBI
NVCT icon

Baxter Bros Inc’s Nuvectis Pharma NVCT Stock Holding History

Baxter Bros Inc’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$112K – 168
2025
Q2 		$112K Hold
15,000
– – 0.01% 147
2025
Q1 		$147K Hold
15,000
– – 0.02% 146
2024
Q4 		$81.2K Buy
15,000
+2,500
+20% +$15.7K 0.01% 155
2024
Q3 		$78.6K Hold
12,500
– – 0.01% 153
2024
Q2 		$79.1K Buy
+12,500
New +$85K 0.01% 153

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Baxter Bros Inc's NVCT Position: Q3 2025 in Review

Baxter Bros Inc sold out of Nuvectis Pharma (NVCT) in Q3 2025, closing a stake of 15,000 shares — an estimated $112K sold.

Baxter Bros Inc first reported a position in NVCT in Q2 2024 and held it in 5 quarters. The position peaked at $147K in Q1 2025. 53 funds tracked by Wall St. Rank hold NVCT as of Q3 2025.

  • Baxter Bros Inc reported no remaining Nuvectis Pharma position as of Q3 2025 after selling out during the quarter.
  • Baxter Bros Inc sold 15,000 Nuvectis Pharma shares in Q3 2025, an estimated $112K.
  • Baxter Bros Inc first reported a position in Nuvectis Pharma in Q2 2024 and held it in 5 quarters.
  • Baxter Bros Inc's Nuvectis Pharma position peaked at $147K in Q1 2025.
  • 53 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2025.

Based on Baxter Bros Inc's 13F filing for Q3 2025, filed 14 Oct 2025.